Fig. 4: Responder characteristics (n = 19). | Nature Medicine

Fig. 4: Responder characteristics (n = 19).

From: Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Fig. 4

NLM was defined as patients with no history of LM (n = 17) or patients whose LM were resected or ablated without recurrence (treated; n = 2). Arrows indicate patients who, at the time of the data cutoff, were ongoing on treatment. a One patient later progressed. b One patient with a RECIST 1.1 response at 6 weeks had surgical resection of a target lesion that was considered clinical progression based on increase from nadir at 12 weeks after receiving steroids for an immune-mediated TRAE and was not confirmed; remaining target lesions then progressed. c Patient with treated LM (all other bars represent patients with no history of LM). NE, not evaluable.

Back to article page